下载PDF
实例探究 > Automated Cellular Cytotoxicity Assays with Antha and Gilson PIPETMAX

Automated Cellular Cytotoxicity Assays with Antha and Gilson PIPETMAX

技术
  • 分析与建模 - 预测分析
  • 功能应用 - 远程监控系统
  • 平台即服务 (PaaS) - 数据管理平台
适用行业
  • 医疗保健和医院
  • 生命科学
适用功能
  • 产品研发
  • 质量保证
用例
  • 数字孪生
  • 预测性维护
  • 远程资产管理
  • 远程控制
服务
  • 云规划/设计/实施服务
  • 软件设计与工程服务
  • 系统集成
挑战
Scientists at Autolus routinely use cytotoxicity assays in the development of novel CAR T-cell therapies. Setting up these assays manually is labour-intensive and time-consuming. While automation can increase throughput, robustness, and walkaway time for scientists, it often requires advanced coding skills. In addition, automating the handling of live cells is not straightforward as they are sensitive and susceptible to lysis.
关于客户
Autolus is a leading clinical-stage biopharmaceutical company in T cell programming technologies, developing precisely targeted, controlled, and highly active Chimeric Antigen Receptor (CAR) T-cell therapies, with the potential to offer cancer patients more effective treatments and care. The company was founded on pioneering cell programming technology developed by Dr Martin Pule and was spun-out from University College London in 2014. The Synthetic Genomics research group at Autolus started working with Synthace in 2019 as it recognized the need to improve the flexibility, robustness, and efficiency of its routine CAR T-cell cytotoxicity assays. The group was looking towards automation solutions that could provide a rapid and scalable approach to physical execution in the lab, which led them to adopt Synthace’s software platform Antha.
解决方案
Synthace’s software platform Antha allows scientists to flexibly plan, test, and execute cytotoxicity assays on selected liquid handlers, with no programming needed. Users can build, simulate, and verify their assays in silico prior to scheduling a physical run. All methods and data are securely stored in the cloud for easy protocol sharing and standardization. Antha empowered Autolus to automate the setup of complex cytotoxicity assays easily, rapidly, and with the flexibility required for therapy development. Scientists showed how three different CAR-transduced effector cells significantly reduced cancer cell growth, while next generation CARs overcame inhibitory cytokine signalling, a major challenge in CAR T-cell therapies. Antha did not impact cell viability or transfer accuracy and achieved comparable results to manual execution, while offering superior pipetting consistency leading to increased assay robustness.
运营影响
  • Antha-driven automated liquid handling of mammalian cells maintained cell viability and transfer accuracy to the same level as manual pipetting, without compromising the results.
  • Antha allowed Autolus scientists to optimize and verify their workflow prior to execution and ensured complete traceability.
  • Antha workflows can be easily adapted for new experiments/devices with a few clicks, without the need to rewrite scripts, reprogram robots, or interact with multiple vendor software.
数量效益
  • Antha provided remarkable pipetting consistency, with CV of 3.66% compared to 23.17% in manual execution.

相关案例.

联系我们

欢迎与我们交流!

* Required
* Required
* Required
* Invalid email address
提交此表单,即表示您同意 IoT ONE 可以与您联系并分享洞察和营销信息。
不,谢谢,我不想收到来自 IoT ONE 的任何营销电子邮件。
提交

Thank you for your message!
We will contact you soon.